AstraZeneca Strengthens Position In COPD Race With Successful Trials

All NewsMarch 27, 2026

AstraZeneca reports Phase 3 success for tozorakimab in COPD, reducing exacerbations and showing strong safety across broad patient groups.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent